DiscernDx Acquires Luminist Labs
April 29, 2020
DiscernDx, a Palo Alto precision medicine company, has acquired Luminist Labs, a privately-held diagnostic platform developer focused on early detection and diagnosis of liver disease. The acquisition will integrate Luminist's data and platform into DiscernDx's multi-omics system to accelerate development of non-invasive diagnostic and prognostic solutions for NASH and other chronic metabolic liver diseases. Terms were not disclosed.
- Buyers
- DiscernDx
- Targets
- Luminist Labs
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
1848 Ventures Acquires Luminest
May 18, 2025
Cloud & SaaS
1848 Ventures, an AI-first venture studio, has acquired Luminest, an AI-based home management startup focused on predictive maintenance and structured property data. The acquisition brings Luminest’s proprietary models and engineering talent into 1848V to accelerate its vertical SaaS initiatives addressing demand generation and job quality for specialty contractors and skilled trades.
-
LumiThera Acquires Diopsys
November 11, 2021
Medical Devices
LumiThera, a commercial-stage ophthalmic medical device company, entered a definitive merger agreement to acquire Diopsys in a stock-for-stock transaction under which Diopsys will become a wholly owned subsidiary of LumiThera. The deal combines Diopsys' visual electrophysiology diagnostic systems with LumiThera's photobiomodulation treatment platform to create a coordinated light-based theranostic approach for diagnosing, treating and monitoring ocular disease.
-
Roche to Acquire LumiraDx Point-of-Care Technology Platform for $295 Million
January 2, 2024
Healthcare Services
LumiraDx has entered into a definitive agreement for Roche to acquire certain companies and related assets within LumiraDx’s point-of-care diagnostics platform business. Roche will pay $295 million at closing, with an additional payment of up to $55 million for reimbursement to fund the platform business until closing.
-
LumiThera Acquires MacuLogix Assets (AdaptDx Pro)
July 26, 2022
Medical Devices
LumiThera, through a wholly owned subsidiary, purchased the assets of MacuLogix, including the AdaptDx Pro dark adaptometer used for early diagnosis of dry age-related macular degeneration (AMD). The acquisition expands LumiThera's diagnostic and monitoring capabilities and complements its Valeda photobiomodulation treatment platform for dry AMD patients.
-
Somatus Acquires Strategic Assets from Lumiata
April 28, 2022
Healthcare Services
Somatus has acquired strategic assets from Lumiata to integrate Lumiata's healthcare AI and predictive analytics into Somatus' RenalIQ platform, improving early identification of people with chronic kidney disease and prediction of disease progression. The deal brings Lumiata talent (including Jessica McCarthy) into Somatus and aims to strengthen care delivery, reduce costs for provider and health-plan partners, and address health inequities.
-
Health Catalyst Acquires Lumeon Limited
August 8, 2024
Healthcare Services
Health Catalyst, Inc. (Nasdaq: HCAT) has completed its acquisition of Lumeon Limited, a digital health company that provides care orchestration software used by provider organizations in the U.S. and United Kingdom. The deal combines Lumeon's Care Orchestration platform with Health Catalyst's analytics and AI capabilities to expand clinical automation, improve care coordination, and support international growth, particularly in the U.K.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.